HeartSciences (NASDAQ:HSCS) Trading Up 1.4% – Here’s What Happened

Posted by Defense World Staff on Sep 26th, 2025

Shares of HeartSciences Inc. (NASDAQ:HSCS – Get Free Report) were up 1.4% during trading on Thursday . The stock traded as high as $3.80 and last traded at $3.74. Approximately 135,273 shares traded hands during mid-day trading, an increase of 55% from the average daily volume of 87,437 shares. The stock had previously closed at $3.69.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of HeartSciences to a “sell” rating in a research report on Saturday, July 26th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.00.

Check Out Our Latest Stock Report on HeartSciences

HeartSciences Stock Up 1.4%

The company has a market cap of $9.91 million, a P/E ratio of -0.45 and a beta of 2.57. The company’s 50-day moving average is $3.52 and its two-hundred day moving average is $3.50.

HeartSciences (NASDAQ:HSCS – Get Free Report) last posted its quarterly earnings results on Thursday, September 11th. The company reported ($1.58) earnings per share for the quarter, beating the consensus estimate of ($2.41) by $0.83. On average, analysts anticipate that HeartSciences Inc. will post -10.01 EPS for the current fiscal year.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC bought a new position in shares of HeartSciences Inc. (NASDAQ:HSCS – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences as of its most recent SEC filing. 17.24% of the stock is owned by hedge funds and other institutional investors.

HeartSciences Company Profile

(Get Free Report)

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.